At the news
? BEARISHIMPACT 5/10 6-K filed Nov 16, 2026 at 08:00 ET
Enlivex entered into a securities purchase agreement for a $7.5 million registered direct offering of ordinary shares (or pre-funded warrants) and accompanying ordinary warrants, priced at $1.315 per share unit (a 10.5% premium to the prior closing price). The offering will close in monthly tranches starting with $500,000 and continuing with $700,000 per month over 10 months, subject to shareholder approval for an increase in authorized share capital. The proceeds are intended for clinical, regulatory, manufacturing, R&D activities, potential acquisitions, and general corporate purposes.
- Aggregate gross proceeds of approximately $7.5 million from the registered direct offering, assuming all closings are consummated.
- Initial closing of $500,000 expected on or about November 17, 2026, with 10 subsequent monthly closings of $700,000 each from December 2026 through September 2027.
- Combined purchase price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a 10.5% premium to the November 13, 2026 closing price.
- Ordinary warrants have an exercise price of $1.578 per share, exercisable immediately, expiring three years from initial closing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access